NASDAQ:CGENCompugen Stock Price, Forecast & News

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CGEN shares have increased by 33.7% and is now trading at $15.82. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Compugen.

Compugen is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Compugen.

Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). During the same period in the previous year, the business posted ($0.14) earnings per share. View Compugen's earnings history.

7 equities research analysts have issued twelve-month price objectives for Compugen's shares. Their forecasts range from $13.00 to $28.00. On average, they expect Compugen's stock price to reach $18.57 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for Compugen.

Media stories about CGEN stock have trended negative on Wednesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Compugen earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Compugen.

Some companies that are related to Compugen include China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Immunovant (IMVT), Twist Bioscience (TWST), Bill.com (RVMD), Alector (ALEC), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX) and Adverum Biotechnologies (ADVM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Gilead Sciences (GILD), Novavax (NVAX), Pluristem Therapeutics (PSTI), Inovio Pharmaceuticals (INO), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $15.82.

Compugen has a market capitalization of $1.08 billion and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.

The official website for Compugen is www.cgen.com.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]